Logo Bruker

Bruker (BRKR) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Bruker · Health Care · ref. ETF XLV · 51 calls · price $56.19
🏆JPI 2026 portfoliosSee tracking →
What the company does: Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions.

📈 Bruker (BRKR) stock price

$56.19+53.9% over range
Oct 14, 25low $32.76 · high $64.75Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
57% recommend buying · 7 analysts
📊 JPI status : Bruker has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 BRKR price target & analyst consensus — price $56.19

The price target · all analysts combined (7 targets)
Highest target · 1 firm of 7$80+42.4%
Median target · of 7 targets$67.5+20.1%
Lowest target · 1 firm of 7$53-5.7%
Current price$56.19
Where these 7 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 686% $62 ↔ $80
Below 114% $53
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $72 (+28 %), call made on October 2, 2026, maturing on October 2, 2027 (12 d ago).

The 4 reliable analysts $68.50+22 %
The 3 other firms $65+16 %
How to read it: the 4 reliable firms are not filtered by optimism — 3 aim above the price, 1 below, hence their $68.50 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 7 ratings (last 6 months)
Strong Buy00%
Buy457%
Hold343%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Bruker? The JPI assistant answers using our backtest data.

💰 Bruker dividend: yield, history & growth › open the full page

0.33%annual yield
That's ~$0.20 per share per year.

📈 Bruker fundamentals: valuation, margins & growth › open the full page

P/E —Net margin -2.0 %Revenue growth +5.2 %Not (yet) profitable

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 12 %
2023
Rev +17%Profit +44%
2024
Rev +14%Profit −74%
2025
Rev +2%Profit −120%

🔎 Detailed analyses

🏛️ Which US Congress members hold Bruker (BRKR)?

1 Congress member has disclosed BRKR buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Bob Gibbs 1× · 38%
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on BRKR

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Needham ↗ 100% +51.5% 2
Jefferies ↗ 100% +33.8% 3
Leerink Swann 100% +24.2% 2
UBS ↗ 75% +9.2% 8
Cantor Fitzgerald ↗ 67% +32.9% 3
Goldman Sachs ↗ 57% +10.1% 7
SVB Leerink 57% +9.9% 7
B of A Securities ↗ 56% +3.9% 9
Barclays ↗ 55% +10.5% 11
Wells Fargo ↗ 50% +9.3% 8
See the other 5 firms
JP Morgan ↗ 0% -48.1% 2
Guggenheim ↗ 0% -16.2% 3
Cleveland Research 0% -11.9% 2
Citigroup ↗ 33% -10.6% 9
Morgan Stanley ↗ 50% -11.0% 2

📊 What $1,000 invested in Bruker would be worth › open the full page

In short — $1,000 invested in Bruker 10 years ago would be worth $2,480 today, i.e. +10%/yr on average. Best year: 2019 (+71%), worst: 2024 (-20%). Price performance, excluding dividends.

If I'd invested $1,000 in Bruker

InvestmentWorth todayGain
1 years ago$1,027+3%
3 years ago$880-12%
5 years ago$1,112+11%
→ See Bruker's full return history + gain calculator

Return by year (Bruker)

YearReturn$1,000 invested at year start
2026 (YTD)+28%$1,277 (+28%)
2025-20%$1,027 (+3%)
2024-20%$819 (-18%)
→ See Bruker's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Bruker

Loading news…

📋 All analyst calls on BRKR

TD Cowen ↗
Oct 13, 26
■ Hold neutral · not a buy · 🎯$62
Today : $56.19 — gap to target +10%
🎯 on BRKR : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Oct 13, 27
Barclays ↗
Oct 7, 26
▲ Overweight · 🎯$70
Price at call : $57.92 — upside +21%
Today : $56.19 — upside +25%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Oct 7, 27
Guggenheim ↗
Oct 1, 26
▲ Buy · 🎯$72
Price at call : $63.24 — upside +14%
Today : $56.19 — upside +28%
🎯 on BRKR : no call matured yet · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Oct 1, 27
▲ Outperform · 🎯$80
Price at call : $64.75 — upside +24%
Today : $56.19 — upside +42%
🎯 on BRKR : no call matured yet · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Sep 29, 27
UBS ↗
Sep 9, 26
■ Neutral neutral · not a buy · 🎯$65
Price at call : $53.56 — gap to target +21%
Today : $56.19 — gap to target +16%
🎯 on BRKR : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 9, 27
Citigroup ↗
Aug 5, 26
■ Neutral neutral · not a buy · 🎯$53
Price at call : $51.27 — gap to target +3%
Today : $56.19 — gap to target -6%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Aug 5, 27
Citigroup ↗
Jul 8, 26
■ Neutral neutral · not a buy · 🎯$60
Price at call : $60.58 — gap to target -1%
Today : $56.19 — gap to target +7%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Jul 8, 27
▲ Outperform · 🎯$70
Price at call : $57.21 — upside +22%
Today : $56.19 — upside +25%
🎯 on BRKR : no call matured yet · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Jul 7, 27
See the other 43 calls, newest to oldest
Guggenheim ↗
Jun 29, 26
▲ Buy · 🎯$70
Price at call : $60.18 — upside +16%
Today : $56.19 — upside +25%
🎯 on BRKR : no call matured yet · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jun 29, 27
Barclays ↗
Jun 24, 26
▲ Overweight · 🎯$60
Price at call : $60.89 — upside -1%
Today : $56.19 — upside +7%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Jun 24, 27
JP Morgan ↗
Jun 8, 26
▲ Overweight · 🎯$65
Price at call : $57.24 — upside +14%
Today : $56.19 — upside +16%
🎯 on BRKR : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Jun 8, 27
UBS ↗
May 8, 26
■ Neutral neutral · not a buy · 🎯$45
Price at call : $44.16 — gap to target +2%
Today : $56.19 — gap to target -20%
🎯 on BRKR : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : May 8, 27
Citigroup ↗
May 7, 26
■ Neutral neutral · not a buy · 🎯$44
Price at call : $44.16 — gap to target -0%
Today : $56.19 — gap to target -22%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : May 7, 27
TD Cowen ↗
May 7, 26
■ Hold neutral · not a buy · 🎯$45
Price at call : $44.16 — gap to target +2%
Today : $56.19 — gap to target -20%
🎯 on BRKR : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : May 7, 27
Barclays ↗
May 7, 26
▲ Overweight · 🎯$53
Price at call : $44.16 — upside +20%
Today : $56.19 — upside -6%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : May 7, 27
Barclays ↗
Apr 15, 26
▲ Overweight · 🎯$45
Price at call : $38.94 — upside +16%
Today : $56.19 — upside -20%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Apr 15, 27
Barclays ↗
Apr 14, 26
▲ Overweight · 🎯$45
Price at call : $39.48 — upside +14%
Today : $56.19 — upside -20%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Apr 14, 27
Guggenheim ↗
Mar 30, 26
▲ Buy · 🎯$50
Price at call : $36.12 — upside +38%
Today : $56.19 — upside -11%
🎯 on BRKR : no call matured yet · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Mar 30, 27
Citigroup ↗
Feb 13, 26
■ Neutral neutral · not a buy · 🎯$40
Price at call : $38.12 — gap to target +5%
Today : $56.19 — gap to target -29%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Feb 13, 27
Goldman Sachs ↗
Feb 13, 26
▼ Sell · 🎯$35
Price at call : $38.12 — upside -8%
Today : $56.19 — upside -38%
🎯 on BRKR : no call matured yet · 📊 on Health : 59.5% · +16.1% (111 calls)
in progress (365j)
matures : Feb 13, 27
TD Cowen ↗
Feb 13, 26
■ Hold neutral · not a buy · 🎯$43
Price at call : $38.12 — gap to target +13%
Today : $56.19 — gap to target -23%
🎯 on BRKR : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Feb 13, 27
Barclays ↗
Feb 13, 26
▲ Overweight · 🎯$50
Price at call : $38.12 — upside +31%
Today : $56.19 — upside -11%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Feb 13, 27
Guggenheim ↗
Jan 26, 26
▲ Buy · 🎯$58
Price at call : $47.67 — upside +22%
Today : $56.19 — upside +3%
🎯 on BRKR : no call matured yet · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jan 26, 27
Citigroup ↗
Jan 16, 26
■ Neutral neutral · not a buy · 🎯$53
Price at call : $49.84 — gap to target +6%
Today : $56.19 — gap to target -6%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Jan 16, 27
TD Cowen ↗
Jan 7, 26
■ Hold neutral · not a buy · 🎯$53
Price at call : $52.48 — gap to target +1%
Today : $56.19 — gap to target -6%
🎯 on BRKR : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Jan 7, 27
Guggenheim ↗
Jan 5, 26
▲ Buy · 🎯$53
Price at call : $52.67 — upside +1%
Today : $56.19 — upside -6%
🎯 on BRKR : no call matured yet · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jan 5, 27
Barclays ↗
Dec 15, 25
▲ Overweight · 🎯$55
Price at call : $44.96 — upside +22%
Today : $56.19 — upside -2%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Dec 15, 26
JP Morgan ↗
Dec 15, 25
▲ Overweight · 🎯$55
Price at call : $44.96 — upside +22%
Today : $56.19 — upside -2%
🎯 on BRKR : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Dec 15, 26
Wells Fargo ↗
Dec 15, 25
▲ Overweight · 🎯$55
Price at call : $44.96 — upside +22%
Today : $56.19 — upside -2%
🎯 on BRKR : 100% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Dec 15, 26
▲ Buy · 🎯$60
Price at call : $45.67 — upside +31%
Today : $56.19 — upside +7%
🎯 on BRKR : 100% (1 call matured) · 📊 on Health : 64.2% · +20.2% (109 calls)
in progress (365j)
matures : Dec 15, 26
Wolfe Research ↗
Dec 10, 25
▲ Outperform · 🎯$60
Price at call : $46.37 — upside +29%
Today : $56.19 — upside +7%
🎯 on BRKR : no call matured yet · 📊 on Health : 46.2% · +2.9% (13 calls)
in progress (365j)
matures : Dec 10, 26
Goldman Sachs ↗
Dec 9, 25
▼ Sell · 🎯$40
Price at call : $45.36 — upside -12%
Today : $56.19 — upside -29%
🎯 on BRKR : no call matured yet · 📊 on Health : 59.5% · +16.1% (111 calls)
in progress (365j)
matures : Dec 9, 26
Rothschild & Co
Nov 20, 25
▲ Buy · 🎯$60
Price at call : $43.84 — upside +37%
Today : $56.19 — upside +7%
🎯 on BRKR : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Nov 20, 26
Wells Fargo ↗
Nov 5, 25
▲ Overweight · 🎯$48
Price at call : $39.31 — upside +22%
Today : $56.19 — upside -15%
🎯 on BRKR : 100% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Nov 5, 26
TD Cowen ↗
Nov 4, 25
■ Hold neutral · not a buy · 🎯$42
Price at call : $40.2 — gap to target +4%
Today : $56.19 — gap to target -25%
🎯 on BRKR : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Nov 4, 26
UBS ↗
Nov 4, 25
■ Neutral neutral · not a buy · 🎯$43
Price at call : $40.2 — gap to target +7%
Today : $56.19 — gap to target -23%
🎯 on BRKR : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Nov 4, 26
Barclays ↗
Nov 4, 25
▲ Overweight · 🎯$45
Price at call : $40.38 — upside +11%
Today : $56.19 — upside -20%
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Nov 4, 26
Barclays ↗
Oct 2, 25
▲ Overweight · 🎯$40
Price at call : $36.98 — upside +8%
Today : $56.19 — upside -29%
Expected +8% · Actual +73% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+72.7%
stock +73% · XLV +16%
matured Oct 2, 26
Wells Fargo ↗
Aug 5, 25
▲ Overweight · 🎯$50
Price at call : $30.66 — upside +63%
Today : $56.19 — upside -11%
Expected +63% · Actual +67% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
+67.2%
stock +67% · XLV +26%
matured Aug 5, 26
Stifel ↗
Aug 5, 25
■ Hold neutral · not a buy · 🎯$40
Price at call : $32.07 — gap to target +25%
Today : $56.19 — gap to target -29%
🎯 on BRKR : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Aug 5, 26
Citigroup ↗
Aug 4, 25
■ Neutral neutral · not a buy · 🎯$38
Price at call : $32.07 — gap to target +18%
Today : $56.19 — gap to target -32%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Aug 4, 26
Barclays ↗
Aug 4, 25
▲ Overweight · 🎯$43
Price at call : $32.07 — upside +34%
Today : $56.19 — upside -23%
Expected +34% · Actual +64% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+63.6%
stock +64% · XLV +24%
matured Aug 4, 26
Jefferies ↗
Aug 4, 25
▲ Buy · 🎯$60
Price at call : $32.07 — upside +87%
Today : $56.19 — upside +7%
Expected +87% · Actual +64% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (1 call matured) · 📊 on Health : 48.3% · +10.7% (116 calls)
+63.6%
stock +64% · XLV +24%
matured Aug 4, 26
▲ Buy · 🎯$50
Price at call : $41.8 — upside +20%
Today : $56.19 — upside -11%
Expected +20% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (1 call matured) · 📊 on Health : 64.2% · +20.2% (109 calls)
+42.9%
stock +43% · XLV +20%
matured Jun 26, 26
Citigroup ↗
May 22, 25
■ Neutral neutral · not a buy · 🎯$40
Price at call : $36.34 — gap to target +10%
Today : $56.19 — gap to target -29%
🎯 on BRKR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : May 22, 26
UBS ↗
May 8, 25
■ Neutral neutral · not a buy · 🎯$45
Price at call : $37.52 — gap to target +20%
Today : $56.19 — gap to target -20%
🎯 on BRKR : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : May 8, 26
Barclays ↗
May 8, 25
▲ Overweight · 🎯$46
Price at call : $37.52 — upside +23%
Today : $56.19 — upside -18%
Expected +23% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on BRKR : 100% (3 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+15.3%
stock +15% · XLV +8%
matured May 8, 26
Goldman Sachs ↗
May 8, 25
■ Neutral neutral · not a buy · 🎯$45
Price at call : $37.52 — gap to target +20%
Today : $56.19 — gap to target -20%
🎯 on BRKR : no call matured yet · 📊 on Health : 59.5% · +16.1% (111 calls)
in progress (365j)
matures : May 8, 26
Stifel ↗
May 8, 25
■ Hold neutral · not a buy · 🎯$48
Price at call : $37.52 — gap to target +28%
Today : $56.19 — gap to target -15%
🎯 on BRKR : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : May 8, 26
Wells Fargo ↗
Apr 17, 25
▲ Overweight · 🎯$60
Price at call : $35.98 — upside +67%
Today : $56.19 — upside +7%
Expected +67% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on BRKR : 100% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
+14.2%
stock +14% · XLV +11%
matured Apr 17, 26
Maxim Group
Sep 27, 13
▲ Buy · 🎯$27
Price at call : $20.54 — upside +31%
Today : $56.19 — upside -52%
Expected +31% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on BRKR : 0% (1 call matured) · 📊 on Health : 0% · -39.1% (4 calls)
-8.0%
stock -8% · XLV +27%
matured Sep 27, 14

Frequently asked questions

Should I buy Bruker stock?

This isn't buy advice. For Bruker, the analyst consensus is "Buy", with an average price target of $67.50 (+20% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Bruker). We show the numbers — you decide.

Is it too late to buy Bruker? How high can it go?

The most bullish analyst target on Bruker is $80.00 (+42% above today's price); the average is $67.50. That's the upside they see. Check how reliable those analysts have actually been on Bruker on our site before trusting it.

Is Bruker still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 15 analysts have a real record on Bruker, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Bruker? The case for and against

The arguments for and against, one by one, from the numbers: why invest in BRKR (and why hesitate).

What has Bruker's past performance been?

Historical returns and a "how much if I had invested" calculator: BRKR performance & returns.

Does Bruker pay a dividend?

Yield, consistency and growth history of the dividend: BRKR's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)